DXB.AU · Dimerix Limited

-

Please sign in to comment on DXB.AU

1 Comment

Admin

4 years, 3 months ago

Dimerix Limited is currently in a long term downtrend where the price is trading 13.4% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Dimerix Limited's total revenue sank by 33.7% to $1K since the same quarter in the previous year.

Its net income has dropped by 31.6% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 11.4% to $-924K since the same quarter in the previous year.

Based on the above factors, Dimerix Limited gets an overall score of 2/5.

ISIN	AU000000DXB7
Sector	Healthcare
Industry	Biotechnology
Exchange	AU
CurrencyCode	AUD

Market Cap	338M
Beta	0.53
PE Ratio	None
Target Price	0.84
Dividend Yield	None

ABOUT

Dimerix Limited

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

DXB.AU · Dimerix Limited

-

Dimerix Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Dimerix Limited using a moving average strategy